Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma
by Alex3917 on Tuesday September 25, 2012 @12:15PM
(#4571131)
"So in theory a startup might be able to get that 20 million figure down to 5 million if they're lean?"
Not likely, MAPS is already as lean as you can get. And they have a big advantage since there have already been dozens or hundreds of previous studies done on MDMA to establish safety.
Not likely, MAPS is already as lean as you can get. And they have a big advantage since there have already been dozens or hundreds of previous studies done on MDMA to establish safety.